Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Schweizer

Showing results (231-240 of 267) with videos related to

Pageof 27
Sort By:
JCO Precision Oncology|August 23, 2024
DNA-Damaging Therapies in Patients With Prostate Cancer and Pathogenic Alterations in Homologous Recombination Repair GenesLaura S Graham, Nicholas C Henderson, Olesia Kellezi, et al.
Prostate Cancer and Prostatic Diseases|February 22, 2024
Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaborationZeynep B Zengin, Nicholas C Henderson, Joseph J Park, et al.
JCI Insight|December 8, 2021
Genomic attributes of homology-directed DNA repair deficiency in metastatic prostate cancerNavonil De Sarkar, Sayan Dasgupta, Payel Chatterjee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2025
Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I StudyMark N Stein, Armelle Vinceneux, Debbie Robbrecht, et al.
The Oncologist|October 22, 2025
Genomic Alterations and Associated Outcomes in Patients with PSMA-Positive Metastatic Castration-Resistant Prostate Cancer treated with 177Lu-PSMA-617Justine Panian, Nicholas C Henderson, Daniel Herchenhorn, et al.
The Journal of Clinical Investigation|July 31, 2019
Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancerMark P Labrecque, Ilsa M Coleman, Lisha G Brown, et al.
Clinical Genitourinary Cancer|November 8, 2020
Response to Neoadjuvant Chemotherapy and Survival in Micropapillary Urothelial Carcinoma: Data From a Tertiary Referral Center and the Surveillance, Epidemiology, and End Results (SEER) ProgramLeonidas N Diamantopoulos, Sarah K Holt, Ali R Khaki, et al.
Journal for Immunotherapy of Cancer|March 22, 2023
First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC)Karen A Autio, Celestia S Higano, Luke Nordquist, et al.
JAMA Network Open|September 18, 2023
Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate CancerClara Hwang, Nicholas C Henderson, Shih-Chun Chu, et al.
Urologic Oncology|May 2, 2025
Prospective evaluation of comprehensive geriatric assessments in multidisciplinary bladder cancer care and implications for personalized vulnerability phenotypingDana Cavanaugh, Sarah K Holt, Erin Dwyer, et al.
Pageof 27

Showing results (231-240 of 267) with videos related to

Sort By:
Pageof 27
JCO Precision Oncology|August 23, 2024
DNA-Damaging Therapies in Patients With Prostate Cancer and Pathogenic Alterations in Homologous Recombination Repair GenesLaura S Graham, Nicholas C Henderson, Olesia Kellezi, et al.
Prostate Cancer and Prostatic Diseases|February 22, 2024
Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaborationZeynep B Zengin, Nicholas C Henderson, Joseph J Park, et al.
JCI Insight|December 8, 2021
Genomic attributes of homology-directed DNA repair deficiency in metastatic prostate cancerNavonil De Sarkar, Sayan Dasgupta, Payel Chatterjee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2025
Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I StudyMark N Stein, Armelle Vinceneux, Debbie Robbrecht, et al.
The Oncologist|October 22, 2025
Genomic Alterations and Associated Outcomes in Patients with PSMA-Positive Metastatic Castration-Resistant Prostate Cancer treated with 177Lu-PSMA-617Justine Panian, Nicholas C Henderson, Daniel Herchenhorn, et al.
The Journal of Clinical Investigation|July 31, 2019
Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancerMark P Labrecque, Ilsa M Coleman, Lisha G Brown, et al.
Clinical Genitourinary Cancer|November 8, 2020
Response to Neoadjuvant Chemotherapy and Survival in Micropapillary Urothelial Carcinoma: Data From a Tertiary Referral Center and the Surveillance, Epidemiology, and End Results (SEER) ProgramLeonidas N Diamantopoulos, Sarah K Holt, Ali R Khaki, et al.
Journal for Immunotherapy of Cancer|March 22, 2023
First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC)Karen A Autio, Celestia S Higano, Luke Nordquist, et al.
JAMA Network Open|September 18, 2023
Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate CancerClara Hwang, Nicholas C Henderson, Shih-Chun Chu, et al.
Urologic Oncology|May 2, 2025
Prospective evaluation of comprehensive geriatric assessments in multidisciplinary bladder cancer care and implications for personalized vulnerability phenotypingDana Cavanaugh, Sarah K Holt, Erin Dwyer, et al.
Pageof 27